In the original article, there was a mistake in the title for **Table 2**, as published. The correct title should be *MNHD, AC, and visual analog scale for pain (VAS) score means at every time-point and 95% CI*.

Similarly, in the sentence "HI, AC, and VAS score were considered as the primary end-points of the study" the acronym HI was used. It has now been changed to MNHD. We also omitted the formula used to calculate the MNHD. A correction has been made to Materials and Methods, sub-section Procedures, Paragraph 1. The corrected paragraph appears below:

During every injection session, the mean number of headache days over 30 days (MNHD), the mean number of abortive medications taken every day (analgesic consumption- AC) and the mean value of the visual analog scale for pain (VAS) score were collected from the headache diaries. MNHD, AC and VAS score were considered as the primary end-points of the study. Mean Number of Headache Days over 30 Days (= Number of headache days in the 1^st^ month after injection + Number of headache days in the 2^nd^ month after injection + Number of headache days in the 3^rd^ month after injection / 90).

We created a CONSORT chart to better explain the number of drop-outs seen during the study. This has been added as Figure [2](#F2){ref-type="fig"} and is cited in Results, sub-section Demographic Analysis and Drop-outs, which is available below:

![Patients and drop-outs.](fneur-09-00641-g0002){#F2}

The analyzed sample was composed by 90 patients, 14 men and 76 women, aged between 35 and 65 years (mean ± SD = 45.21 ± 10.12). The most overused drugs were triptans (71/90-78.89%) followed by non-steroidal anti-inflammatory drugs (NSAIDs) (41/90-45.56%), whilst only 3 patients overused combination drugs (3-3.33%). Oral drugs were taken by the 88% of patients, the 20% used also intramuscular drugs and the 15% used also rectal formulations. Thirty-four patients used a first class preventive treatment other than OnabotA: 4 used anti-hypertensive drugs, 15 antidepressants and 15 antiepileptics. No patients took simultaneously two first class preventive treatments. Patients who took anti-hypertensive drugs stopped them before the 7^th^ injection cycle, due to inefficacy (3 patients) and one adverse event (hypotension), so data from these patients were not pooled in the two-way analysis of variance. Eight patients underwent the 195 U treatment during no more than one injection cycle each. Eighty-eight out of 90 patients (97.8%) fulfilled the diagnostic criteria for chronic migraine at the beginning of the study. After the first year of treatment patients suffering for CM were 37 out of 59 (62.72%), becoming the 66.67% at the second year (14 out of 21 patients) and the 53.85% at the 3^rd^ year (7 out 13 patients). The proportion of chronic migraineurs at the baseline is lower than the ones at the 1^st^, 2^nd^ and 3^rd^ year. Those ones were not significantly different (Fisher\'s exact test- data not shown). All 88 chronic migraineurs at the beginning were also considerable as MOH-sufferers. After the first year of therapy their percentage decreased to the 59.32% (35 out of 59 patients). At the second year the proportion of MOH-sufferers increased at 13 out of 21 (61.9%) and at the third year became of 7 out of 13 patients (53.85%). MOH-sufferers proportion at the baseline was significantly higher than the ones at future time-points, but no significant differences were found between them (Fisher\'s exact test, data not shown). Of the 90 patients enrolled, 24 changed the dose and/or type of preventive treatment other than OnabotA due to side effects and, even if they continued OnabotA injections, further data were not pooled in the analysis. One patient tried a muscular electric stimulator without consulting physicians and her data from that moment onward were not pooled in the analysis. Globally, 14 patients stopped OnabotA injection during the observation (14/90-15.56%): one patient decided to stop treatment because she was almost pain-free, three patients were lost at follow-up and ten patients discontinued OnabotA due to lack of efficacy. No drop-outs were caused by OnabotA-related AEs. Globally, only patients who discontinued OnabotA treatment because of lack of benefit and those ones who were lost at follow-up were considered as drop-outs, giving an overall number of drop-outs of 13/90 (14.44%). A CONSORT flow-chart was added for graphically explained the drop-outs reasons (Figure [2](#F2){ref-type="fig"}).

The authors apologize for these errors and hope the clarification aids readers\' understanding of the article. These changes do not change the scientific conclusions of the article in any way.
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